NEW DRUGS
FOR INCREASING
RESPIRATORY DISEASES
BY A MULTIMODAL APPROACH
A DRUG PLATFORM
BASED ON RECOMBINANT AAT
NEW THERAPIES FOR RESPIRATORY DISEASES
We develop a drug platform for the treatment of respiratory diseases. It is based on a proprietary recombinant variant of alpha-1 antitrypsin (AAT) providing multimodal effects to target neutrophilic respiratory inflammation. Our lead product candidate ATL-105 is an inhalation therapy for non-CF bronchiectasis, COPD, asthma, and pulmonary infections.
PROTEIN INHALATION TECHNOLOGY
FOR EFFECTIVE drug delivery
Medications for respiratory diseases are most effective when delivered directly to the airways. Our product candidates use cutting-edge aerosol inhalation technology for drug administration to the respiratory tract. For fast onset and optimal local effect in the lungs.
FOUNDED BY EXPERTS
AATec was founded by a team of senior experts from clinical research, biopharmaceutical development, product industrialization and business. All have a clear vision and interdisciplinary experience.
GLOBAL
IMPACT
Respiratory diseases have global societal impact. We design our products for people everywhere. Accessible and with worldwide reach.
OUR PARTNERS
